Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001171843-25-002953
Filing Date
2025-05-08
Accepted
2025-05-08 08:01:09
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cmpx20250331_10q.htm   iXBRL 10-Q 806927
2 EXHIBIT 31.1 ex_809094.htm EX-31.1 13944
3 EXHIBIT 31.2 ex_809097.htm EX-31.2 13498
4 EXHIBIT 32.1 ex_809098.htm EX-32.1 6102
5 EXHIBIT 32.2 ex_809099.htm EX-32.2 6370
  Complete submission text file 0001171843-25-002953.txt   4763651

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cmpx-20250331.xsd EX-101.SCH 42604
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmpx-20250331_def.xml EX-101.DEF 290259
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpx-20250331_lab.xml EX-101.LAB 263925
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpx-20250331_pre.xml EX-101.PRE 319604
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cmpx-20250331_cal.xml EX-101.CAL 35682
66 EXTRACTED XBRL INSTANCE DOCUMENT cmpx20250331_10q_htm.xml XML 751545
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39696 | Film No.: 25923967
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)